
|Videos|May 12, 2017
Dr. Loeb on Active Surveillance for Prostate Cancer
Author(s)Stacy Loeb, MD
Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses active surveillance for patients with low-risk prostate cancer.
Advertisement
Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses active surveillance for patients with low-risk prostate cancer.
Active surveillance is a growing management option for patients with low-risk prostate cancer, states Loeb.
One of the concerns is that the risk classification for patients with prostate cancer is not completely accurate, explains Loeb. Genomic tests are being studied to confirm that patients are categorized appropriately.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Ziftomenib Plus 7+3 Elicits Durable Responses in Newly Diagnosed NPM1-Mutant and KMT2A-Rearranged AML
2
Gilteritinib Yields Comparable Efficacy vs Midostaurin in Newly Diagnosed FLT3-Mutated AML but Fails to Meet Phase 3 Primary End Point
3
Dr Voorhees on Efficacy Data for Talquetamab-Based Combos in R/R Myeloma From MonumenTAL-3
4
Tuspetinib Plus Venetoclax and Azacitidine Is Safe and Effective Across Molecular Subgroups in Newly Diagnosed AML
5







































































